High-flow medical oxygen insufflation

Phase 3Small molecule

High-flow medical oxygen insufflation is one of 5 small molecule programs targeting Hypoxemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoxemiaEnrolling by invitation

HypoxemiaPhase 3

Enrolling by invitation

Competition

Competitive Landscape

6 competitors in Hypoxemia

#DrugCompanyPhaseTrials

Esmeron

FFresenius Kabi USA, LLC

Approved

1 2

Inomax

MMallinckrodt

Approved

—3

High-flow medical oxygen insufflation

OOutcomes'10

Phase 3

1 4

Inhaled Nitric Oxide

LLee's Pharmaceutical Limited

Preclinical

2 5

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoxemia1 trial

Usefulness of High-flow Oxygen Therapy of Patients at Risk of Hypoxemia Undergoing Digestive Endoscopy Under Deep Sedation

Enrolling by invitation·OOutcomes'10·Phase 4·NCT07439822·326 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for High-flow medical oxygen insufflation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High-flow medical oxygen insufflation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High-flow medical oxygen insufflation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Outcomes'10 company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOutcomes'10

High-flow medical oxygen insufflation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoxemia1 trial

References

Drug Info

Quick Facts

Related News